What is a stock summary page? Click here for an overview.
Business Description
Aurinia Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA05156V1022
Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Geographically, it derives maximum revenue from the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.52 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | 2.5 | |||||
| Interest Coverage | 3.81 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.84 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 65.8 | |||||
| 3-Year Book Growth Rate | -7.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 86.97 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 19.23 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.09 | |||||
| 9-Day RSI | 59.34 | |||||
| 14-Day RSI | 54.87 | |||||
| 3-1 Month Momentum % | -15.17 | |||||
| 6-1 Month Momentum % | 14.11 | |||||
| 12-1 Month Momentum % | 60.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.57 | |||||
| Quick Ratio | 4.17 | |||||
| Cash Ratio | 3.67 | |||||
| Days Inventory | 507.19 | |||||
| Days Sales Outstanding | 47.05 | |||||
| Days Payable | 83.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 2.61 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.99 | |||||
| Operating Margin % | 7.83 | |||||
| Net Margin % | 2.45 | |||||
| FCF Margin % | 19.05 | |||||
| ROE % | 1.54 | |||||
| ROA % | 1.07 | |||||
| ROIC % | 10.12 | |||||
| 3-Year ROIIC % | 219.14 | |||||
| ROC (Joel Greenblatt) % | 9.82 | |||||
| ROCE % | 2.69 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 169.43 | |||||
| Forward PE Ratio | 18 | |||||
| PE Ratio without NRI | 48.69 | |||||
| Price-to-Owner-Earnings | 42.89 | |||||
| PS Ratio | 5.25 | |||||
| PB Ratio | 3.17 | |||||
| Price-to-Tangible-Book | 3.18 | |||||
| Price-to-Free-Cash-Flow | 28.52 | |||||
| Price-to-Operating-Cash-Flow | 28.34 | |||||
| EV-to-EBIT | 72 | |||||
| EV-to-EBITDA | 27.88 | |||||
| EV-to-Revenue | 3.76 | |||||
| EV-to-Forward-Revenue | 3.41 | |||||
| EV-to-FCF | 19.58 | |||||
| Price-to-GF-Value | 0.6 | |||||
| Price-to-Graham-Number | 2.62 | |||||
| Price-to-Net-Current-Asset-Value | 4.35 | |||||
| Price-to-Net-Cash | 6.37 | |||||
| Earnings Yield (Greenblatt) % | 1.39 | |||||
| FCF Yield % | 3.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aurinia Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 217.645 | ||
| EPS (TTM) (€) | 0.045 | ||
| Beta | 1.74 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.37 | ||
| Volatility % | 35.96 | ||
| 14-Day RSI | 54.87 | ||
| 14-Day ATR (€) | 0.179149 | ||
| 20-Day SMA (€) | 7.4813 | ||
| 12-1 Month Momentum % | 60.84 | ||
| 52-Week Range (€) | 4.357 - 9.73 | ||
| Shares Outstanding (Mil) | 137.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aurinia Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aurinia Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aurinia Pharmaceuticals Inc Frequently Asked Questions
What is Aurinia Pharmaceuticals Inc(FRA:IKAP)'s stock price today?
The current price of FRA:IKAP is €7.71. The 52 week high of FRA:IKAP is €9.73 and 52 week low is €4.36.
When is next earnings date of Aurinia Pharmaceuticals Inc(FRA:IKAP)?
The next earnings date of Aurinia Pharmaceuticals Inc(FRA:IKAP) is 2025-05-02 Est..
Does Aurinia Pharmaceuticals Inc(FRA:IKAP) pay dividends? If so, how much?
Aurinia Pharmaceuticals Inc(FRA:IKAP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers